All News

Ipsen is redefining a standard for success in innovation with its local Dutch affiliate

Prix Galien 2011 sponsorship brochure

Hotels, Convention Centers and Convention & Visitor Bureaus

The Promise Of Translational Medicine

The mediterranean nation has endeared itself to foreign businesses over the past decades, adtively positioning itself as an appealing epicenter of global pharma interest

PharmExec edit calendar revised and smaller size

After many years of building up an impressive resource base, the industry is finally ready to take advantage of the wave of enthusiasm and interest surounding pharma and biotech that is sweeping the nation

June 2010 Sworn Statement

Once silent, an emerging market raises its voice

September 21, 2010.

September 08, 2010.

In a huge blow to Eli Lilly's Alzheimer's pipeline, the drug giant was forced to end two clinical trials due to the fact that the treatment was actually making patients' memory recall worse.

Head-and-neck cancer treatment trial flops in Phase 3 trials causing Amgen stock to drop. The first-line therapy failed first and secondary goals compared with chemotherapy alone.

In the wake of FDA's refusal to approve the lead drug in NicOx's pipeline, the French firm has decided to close its US headquarters.

An industry struggling to meet expectations for new science may find the best strategy is the "controlled burn."

August 2, 2010.

Bonuses for reps at GlaxoSmithKline will soon be based on customer feedback and adherence to company policy, not sales targets. The move promises to transform sales & marketing, but the company offered few details about how the plan will be implemented.

Just weeks after ending tanezunab clinical studies in osteoarthritis patients, the drug giant is ceasing additional trials for two other indications.

July 14, 2010.

John Castellani received the nod from PhRMA on Tuesday to take over the role of president and CEO in September.

Vivus's weight-loss drug Qnexa is heading into an FDA review with the backing of generally positive study data. Will FDA give the thumbs up? Depends on how severe it thinks the side effects are.

Focus Reports discusses kep questions regarding France's pharma industry

GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.

Emerging Pharma Leaders 2010

FDA's meeting on the adoption of REMS for certain prescription opioids doesn't begin until July 22, but the agency's proposal released Tuesday portends a meeting fraught with conflict over the balance between curbing abuse and protecting patient access.